Babesia Patents (Class 424/270.1)
-
Patent number: 8709445Abstract: This invention provides compositions for inducing an immune response in a vertebrate host against a protozoan parasite. In certain embodiments the composition comprises a protozoan parasite comprising a psoralen-modified DNA, whereby said protozoan parasite is killed but metabolically active (KBMA); and optionally a Toll-like receptor agonist.Type: GrantFiled: July 31, 2008Date of Patent: April 29, 2014Assignee: Los Angeles Biomedical Research Institute at Harbor-UCLA Medical CenterInventors: Noah A. Craft, Kevin W. Bruhn, Ron A. Birnbaum
-
Publication number: 20130287786Abstract: The present invention relates to the field of veterinary parasitology, especially of canine Babesiosis. In particular the invention relates to a polypeptide being a novel canine Babesia antigen (CBA), or fragments thereof, and to compositions comprising this antigen, to nucleic acids encoding the antigen, antibodies against the antigen, and medical uses of this antigen, fragments, antibodies, or encoding nucleic acids. In particular the invention relates to the use of such components in vaccines against canine Babesiosis.Type: ApplicationFiled: December 28, 2011Publication date: October 31, 2013Inventors: Theodorus Petrus Maria Schetters, Karina Moubri-Menage, Jose Kleuskens, Andreas Walter Claudius Rohwer
-
Patent number: 8388981Abstract: Disclosed are the cloning and expression of novel antigens in Babesia microti. The recombinant polypeptides are highly immunogenic. The polypeptides of the present invention provide the basis of a diagnostic assay that is sensitive, rapid and accurate using patient's sera. Also disclosed is an IgG and IgM ELISA using two novel recombinant antigens in the diagnosis of Babesia infection.Type: GrantFiled: April 5, 2012Date of Patent: March 5, 2013Assignee: Medical Diagnostic Laboratories, LLCInventors: John G. Hoey, Hannah Venit, Martin E. Adelson, Eli Mordechai, Fernando Valois-Cruz
-
Patent number: 8216593Abstract: The present invention includes compositions and methods for the development and use of a vaccine that includes one or more FusM antigens in a carrier adapted to trigger a FusM-specific immune response in the human blood stream.Type: GrantFiled: September 15, 2007Date of Patent: July 10, 2012Assignees: Board of Regents, The University of Texas System, Imperial College of LondonInventors: William J. Snell, Yanjie Liu, Robert E. Sinden, Oliver Billker, Rita Tewari
-
Publication number: 20120093871Abstract: Modified protozoa parasites comprising simultaneous expression on its surface of at least two ariable surface proteins (VSP). The modified protozoa may also simultaneously express the complete repertoire of variable surface proteins. Protozoa show reduced expression of Dicer, RNA-dependant RNA-plymerase (RdRP) enzymes or both, wherein the RdRP gene and/or the Dicer gene has been silenced. The protozoan may be any protozoan showing an antigenic variation mechanism.Type: ApplicationFiled: December 2, 2009Publication date: April 19, 2012Inventor: Hugo Daniel Lujan
-
Patent number: 8084044Abstract: An object of the present invention is to provide a protein or peptide antigen and an antibody against it, for use in the diagnosis, prevention, or treatment of diseases associated with Pseudomonas aeruginosa. According to the present invention, there is provided a protein or peptide derived from Pseudomonas aeruginosa outer membrane protein PA0427 and an antibody against it, for use in the diagnosis, prevention, or treatment of diseases associated with Pseudomonas aeruginosa.Type: GrantFiled: March 30, 2007Date of Patent: December 27, 2011Assignee: Meiji Seika Kaisha, Ltd.Inventors: Jiro Tanaka, Fukuichi Ohsawa, Takafumi Okutomi, Hiroshi Nagaso, Masashi Kumagai, Takahisa Suzuki, Keiko Otsuka
-
Publication number: 20110182847Abstract: Improved (safer and more effective) methods of therapy using TNF-R agonists, e.g., CD40 agonists are provided. These methods provide for the addition of an amount of a type 1 interferon and/or a TLR agonist that is effective to prevent or reduce the toxicity (liver toxicity) that may otherwise result in some patients of the TNF-R agonist is used as a monotherapy (without the type 1 interferon and/r TLR agonist).Type: ApplicationFiled: June 16, 2008Publication date: July 28, 2011Inventors: Randolph Noelle, Ross Kedl, Cory Ahonen
-
Publication number: 20110091526Abstract: Compositions and methods for the development and use of a vaccine that includes one or more FusM antigens in a carrier adapted to trigger a FusM-specific immune response in the human blood stream are disclosed herein.Type: ApplicationFiled: October 6, 2010Publication date: April 21, 2011Applicants: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM, IMPERIAL COLLEGE OF LONDONInventors: William J. Snell, Yanjie Liu, Oliver Billker, Robert E. Sinden, Rita Tewari
-
Publication number: 20100310606Abstract: This invention provides compositions for inducing an immune response in a vertebrate host against a protozoan parasite. In certain embodiments the composition comprises a protozoan parasite comprising a psoralen-modified DNA, whereby said protozoan parasite is killed but metabolically active (KBMA); and optionally a Toll-like receptor agonist.Type: ApplicationFiled: July 31, 2008Publication date: December 9, 2010Applicant: LOS ANGELES BIOMEDICAL RESEARCH INSTITUTE AT HARBOR-UCLA MEDICAL CENTERInventors: Noah A. Craft, Kevin W. Bruhn, Ron A. Birnbaum
-
Patent number: 7799330Abstract: The invention relates to a Piroplasmid protein or an immunogenic fragment of the protein, and to a nucleic acid encoding the Piroplasmid protein or immunogenic fragment. Furthermore, the invention relates to cDNA fragments, recombinant DNA molecules and live recombinant carriers comprising the nucleic acid. Also the invention relates to host cells comprising the cDNA fragments, recombinant DNA molecules and live recombinant carriers. Finally, the invention relates to vaccines comprising a Piroplasmid protein or an immunogenic fragment of the protein, to methods for the preparation of such vaccines, to the use of such proteins or fragments for vaccine purposes, and to diagnostic tests.Type: GrantFiled: November 21, 2008Date of Patent: September 21, 2010Assignee: Universiteit Utrecht Holding B.V.Inventors: Erik de Vries, Fasila Razzia Gaffar, Ana Patricia Yatsuda, Theodorus Cornelis Schaap
-
Publication number: 20100040615Abstract: The invention relates to a digalactolipidic antigen exposed on the surface of apicomplex parasites, in the form of a vegetable-type digalactoglycerolipid, and adapted for inducing the production of specific antibodies capable of inhibiting the proliferation and/or the invasive properties of said parasites; the invention also relates to a derived antibody or functional antibody fragment, and to their diagnostic, immunotherapeutic and vaccine applications in human beings or animals.Type: ApplicationFiled: February 7, 2008Publication date: February 18, 2010Applicants: COMMISSARIAT A L'ENERGIE ATOMIQUE, CENTRE NATIONAL DE LA RECHERCHE SEIENTIFIQUEInventors: Cyrille Botte, Nadia Saidani, Maryse Block, Jean-Francois Dubremetz, Henri Vial, Marie-France Cesbron-Delauw, Corinne Mercier, Eric Marechal
-
Patent number: 7479284Abstract: The present invention relates to nucleic acid sequences encoding novel Babesia canis associated proteins and to cDNA fragments, recombinant DNA molecules and live recombinant carriers comprising these sequences. Furthermore, the invention relates to host cells comprising such nucleic acid sequences, cDNA fragments, recombinant DNA molecules and live recombinant carriers. Also, the invention relates to proteins encoded by these nucleotide sequences, to vaccines for combating Babesia canis infections comprising these proteins or genetic material encoding these proteins and methods for the preparation of vaccines. Another embodiment of the invention relates to these Babesia canis associated proteins for use in vaccines and to the use of the Babesia canis associated proteins in the manufacture of vaccines.Type: GrantFiled: October 11, 2005Date of Patent: January 20, 2009Assignee: Intervet International B.V.Inventors: Theodorus Petrus Maria Schetters, Bernard Pierre Dominique Carcy, Pascal Robert Drakulovski, Andre Francois Gorenflot
-
Publication number: 20080317786Abstract: The present invention relates to methods for stable transfection of Babesia parasites, and for vaccines conferring immunity against parasitic arthropods.Type: ApplicationFiled: May 5, 2008Publication date: December 25, 2008Applicants: The United States of America, As represented by the Secretary of Agriculture, Washington State University Research FoundationInventors: Carlos E. Suarez, Donald P. Knowles, JR., Terry F. McElwain
-
Patent number: 7465459Abstract: The invention relates to a Piroplasmid protein or an immunogenic fragment of the protein, and to a nucleic acid encoding the Piroplasmid protein or the immunogenic fragment. Furthermore, the invention relates to cDNA fragments, recombinant DNA molecules and live recombinant carriers comprising the nucleic acid. Also the invention relates to host cells comprising the cDNA fragments, recombinant DNA molecules and live recombinant carriers. Finally, the invention relates to vaccines comprising a Piroplasmid protein or an immunogenic fragment of the protein, to methods for the preparation of such vaccines, to the use of such proteins or fragments for vaccine purposes, and to diagnostic tests.Type: GrantFiled: September 14, 2004Date of Patent: December 16, 2008Assignee: Universiteit Utrecht Holding B.V.Inventors: Erik de Vries, Fasila Razzia Gaffar, Ana Patricia Yatsuda, Theodorus Cornelis Schaap
-
Patent number: 7390626Abstract: ELISA, Western Blot, and a peptide-based ELISA were applied to clinical specimens from patients with clinical symptoms of tick borne diseases, including Lyme disease. Peptides from different components of Borrelia during different cycles, including peptides from outer surface protein, leukocyte function associated antigens, immunodominant antigens, variable major proteins, and peptides from decorin-binding proteins of Borrelial subspecies (B. sensu stricto. B. afzelii, B. garinii) were used. Antibodies against specific peptides from Babesia and Ehrlichia were also measured.Type: GrantFiled: February 25, 2005Date of Patent: June 24, 2008Assignee: Immunosciences Lab., Inc.Inventor: Aristo Vojdani
-
Patent number: 7326543Abstract: The present invention provides a gene encoding a protein from merozoite of Babesia caballi, a recombinant protein of Babesia caballi, and an antibody capable specifically binding to a 48 kDa protein of rhoptry of Babesia caballi merozoite. In accordance with the present invention, it is possible to stably prepare the 48 kDa protein of rhoptry of Babesia caballi and the gene encoding said protein in a large amount with the recombinant DNA technique. The present invention also provides a method for diagnosing equine babesiasis which comprises either specifically detecting anti-Babesia caballi antibody present in equine blood by using the recombinant protein of present invention as an antigen or detecting the presence of Babesia caballi merozoite in equine blood by using the antibody of the present invention.Type: GrantFiled: June 9, 2004Date of Patent: February 5, 2008Assignees: Juridical Foundation The Chemo-Sero-Therapeutic Research InstituteInventors: Hiromi Ikadai, Ikuo Igarashi, Naoyoshi Suzuki, Hideyuki Nagasawa, Kozo Fujisaki, Takeshi Mikami
-
Patent number: 7276232Abstract: The present invention relates to compositions containing different stages of pathogenic protozoans in a gel and to their use for controlling rodents.Type: GrantFiled: May 4, 2001Date of Patent: October 2, 2007Assignee: Bayer CropScience AGInventors: Jochen Kalbe, Thomas Böcker, Stefan Endepols, Thomas Jäkel, Sermasakdi Hongnark
-
Patent number: 7090849Abstract: The present invention relates to nucleic acid sequences encoding novel Babesia canis associated proteins and to cDNA fragments, recombinant DNA molecules and live recombinant carriers comprising these sequences. Furthermore, the invention relates to host cells comprising such nucleic acid sequences, cDNA fragments, recombinant DNA molecules and live recombinant carriers. Also, the invention relates to proteins encoded by these nucleotide sequences, to vaccines for combating Babesia canis infections comprising these proteins or genetic material encoding these proteins and methods for the preparation of vaccines. Another embodiment of the invention relates to these Babesia canis associated proteins for use in vaccines and to the use of the Babesia canis associated proteins in the manufacture of vaccines.Type: GrantFiled: February 28, 2002Date of Patent: August 15, 2006Assignee: Akzo Nobel N.V.Inventors: Theodorus Petrus Maria Schetters, Bernard Pierre Dominique Carcy, Pascal Robert Drakulovski
-
Patent number: 7063967Abstract: Aminoalkyl glucosaminide phosphate (AGP) compounds that are adjuvants and immunoeffectors are described and claimed. The compounds have a 2-deoxy-2-amino glucose in glycosidic linkage with an aminoalkyl (aglycon) group. Compounds are phosphorylated at the 4 or 6 carbon on the glucosaminide ring and comprise three 3-alkanoyloxyalkanoyl residues. The compounds augment antibody production in immunized animals as well as stimulate cytokine production and activate macrophages. Compositions and methods for using the compounds as adjuvants and immunoeffectors are also disclosed.Type: GrantFiled: January 8, 2002Date of Patent: June 20, 2006Assignee: Corixa CorporationInventors: David A. Johnson, C. Gregory Sowell
-
Patent number: 6855319Abstract: The present invention provides a gene encoding a protein from merozoite of Babesia caballi, a recombinant protein of Babesia caballi, and an antibody capable specifically binding to a 48 kDa protein of rhoptry of Babesia caballi merozoite. In accordance with the present invention, it is possible to stably prepare the 48 kDa protein of rhoptry of Babesia caballi and the gene encoding said protein in a large amount with the recombinant DNA technique. The present invention also provides a method for diagnosing equine babesiasis which comprises either specifically detecting anti-Babesia caballi antibody present in equine blood by using the recombinant protein of present invention as an .antigen or detecting the presence of Babesia caballi merozoite in equine blood by using the antibody of the present invention.Type: GrantFiled: August 13, 1999Date of Patent: February 15, 2005Assignees: Juridical Foundation the Chemo-Sero-Therapeutic Research InstituteInventors: Hiromi Ikadai, Ikuo Igarashi, Naoyoshi Suzuki, Hideyuki Nagasawa, Kozo Fujisaki, Takeshi Mikami
-
Patent number: 6607725Abstract: A conjugate vaccine for Nontypeable Haemophilus influenzae comprising lipooligosaccharide from which esterified fatty acids have been removed conjugated to an immunogenic carrier. The vaccine is useful for prevention of otitis media and respiratory infections in mammals.Type: GrantFiled: February 20, 2001Date of Patent: August 19, 2003Assignee: The United States of America as represented by the Department of Health and Human ServicesInventors: Xin-Xing Gu, Chao-Ming Tsai, David J. Lim, John B. Robbins
-
Patent number: 6569433Abstract: Compounds and methods for the diagnosis and treatment of B. microti infection are disclosed. The compounds provided include polypeptides that contain at least one antigenic portion of a B. microti antigen and DNA sequences encoding such polypeptides. Antigenic epitopes of such antigens are also provided, together with pharmaceutical compositions and vaccines comprising such polypeptides, DNA sequences or antigenic epitopes. Diagnostic kits containing such polypeptides, DNA sequences or antigenic epitopes and a suitable detection reagent may be used for the detection of B. microti infection in patients and biological samples. Antibodies directed against such polypeptides and antigenic epitopes are also provided.Type: GrantFiled: May 10, 2000Date of Patent: May 27, 2003Assignee: Corixa CorporationInventors: Steven G. Reed, Michael J. Lodes, Raymond L. Houghton, Paul R. Sleath, Patricia D. McNeill, Mary J. Homer, Heather Secrist
-
Publication number: 20030091598Abstract: Compounds and methods for the diagnosis and treatment of Babesia sp. WA1 infection are disclosed. The compounds provided include polypeptides that contain at least one immunogenic portion of a Babesia sp. WA1 antigen and polynucleotides encoding such polypeptides. Pharmaceutical compositions and immunogenic compositions comprising such polypeptides or polynucleotides are also provided. Diagnostic kits containing such polypeptides or polynucleotides and a suitable detection reagent may be used for the detection of Babesia sp. WA1 infection in patients and biological samples. Antibodies directed against such polypeptides are also provided.Type: ApplicationFiled: August 30, 2002Publication date: May 15, 2003Applicant: Corixa CorporationInventors: Mary J. Homer, Michael J. Lodes, Raymond L. Houghton, David H. Persing, Patricia D. McNeill
-
Patent number: 6451315Abstract: Compounds and methods for the diagnosis and treatment of B. microti infection are disclosed. The compounds provided include polypeptides that contain at least one antigenic portion of a B. microti antigen, DNA sequences encoding such polypeptides, and fusion proteins comprising such polypeptides. Antigenic epitopes of such antigens are also provided, together with pharmaceutical compositions and vaccines comprising such polypeptides, DNA sequences, fusion proteins or antigenic epitopes. Diagnostic kits containing such polypeptides, DNA sequences, fusion proteins or antigenic epitopes and a suitable detection reagent may be used for the detection of B. microti infection in patients and biological samples. Antibodies directed against such polypeptides and antigenic epitopes are also provided.Type: GrantFiled: March 17, 2000Date of Patent: September 17, 2002Assignee: Corixa CorporationInventors: Steven G. Reed, Michael J. Lodes, Raymond L. Houghton, Paul R. Sleath, Patricia D. McNeill
-
Patent number: 6306396Abstract: Compounds and methods for the diagnosis and treatment of B. microti infection are disclosed. The compounds provided include polypeptides that contain at least one antigenic portion of a B. microti antigen and DNA sequences encoding such polypeptides. Antigenic epitopes of such antigens are also provided, together with pharmaceutical compositions and vaccines comprising such polypeptides, DNA sequences or antigenic epitopes. Diagnostic kits containing such polypeptides, DNA sequences or antigenic epitopes and a suitable detection reagent may be used for the detection of B. microti infection in patients and biological samples. Antibodies directed against such polypeptides and antigenic epitopes are also provided.Type: GrantFiled: October 1, 1996Date of Patent: October 23, 2001Assignee: Corixa CorporationInventors: Steven G. Reed, Michael J. Lodes, Raymond Houghton, Paul R. Sleath
-
Patent number: 6183976Abstract: Compounds and methods for the diagnosis and treatment of B. microti infection are disclosed. The compounds provided include polypeptides that contain at least one antigenic portion of a B. microti antigen and DNA sequences encoding such polypeptides. Antigenic epitopes of such antigens are also provided, together with pharmaceutical compositions and vaccines comprising such polypeptides, DNA sequences or antigenic epitopes. Diagnostic kits containing such polypeptides, DNA sequences or antigenic epitopes and a suitable detection reagent may be used for the detection of B. microti infection in patients and biological samples. Antibodies directed against such polypeptides and antigenic epitopes are also provided.Type: GrantFiled: April 24, 1997Date of Patent: February 6, 2001Assignee: Corixa CorporationInventors: Steven G. Reed, Michael J. Lodes, Raymond Houghton, Paul R. Sleath